Intrahepatic Cholestasis
📧 Sign up to get email alerts when something new happens for Intrahepatic Cholestasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Pediatric Evaluation and Registry for Liver Cholestasis in Canada
This clinical trial registry update describes a Pediatric Evaluation and Registry for Liver Cholestasis in Canada. It focuses on Progressive…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Update indicating the LOGIC genetic study of intrahepatic cholestasis is currently suspended.
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating REMAXA enteric-coated tablets and REMAXOL infusion for intrahepatic cholestasis has completed.
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
This ClinicalTrials.gov entry reports an ongoing study examining the genotype-phenotype relationship between cryptogenic cholestasis and fam…
-
CLINICAL_TRIALS withdrawal · 2023-02-09Clinical Trial Update: BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases [Phase 2, Phase 3]
A pediatric trial evaluating BSEP function rescue in hereditary cholestatic diseases has been withdrawn after Phase 2/3 participation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2021-12-17EMA Application withdrawn: Livmarli (Maralixibat chloride) — FGK Representative Service GmbH
The EMA has withdrawn the application for Livmarli (maralixibat chloride) represented by FGK Representative Service GmbH.